Jingning Li

Jingning Li possesses extensive experience in analytical research and development, specializing in method development for biopharmaceuticals. Currently serving as Associate Director at NextCure, Inc., since May 2020, Jingning has previously held senior management positions at GSK and Novavax, where responsibilities included leading teams in method development for vaccines, characterizing protein purity, and participating in filings for investigational new drugs (IND). At GSK, key contributions involved managing assay development for recombinant protein and mRNA vaccines while employing quality by design (QbD) principles. Early career roles at MedImmune and Human Genome Sciences focused on protein characterization and formulation studies utilizing various analytical techniques. Jingning holds a Master’s degree in Bioorganic Chemistry from The Catholic University of America and a Bachelor’s degree in Pharmaceutical Sciences from Peking University.